DALLAS, Texas, October 3, 2022 /PRNewswire/ -- Galderma announced today its continued partnership with National Breast Cancer Foundation Inc. (NBCF), one of the leading breast cancer organizations in the world.

• New data on Nemluvio^® (nemolizumab), including an oral e-poster presentation characterizing the impact of Nemluvio in different pruriginous lesion types in prurigo nodularis from the phase III OLYMPIA program, and post-hoc analyses exploring the continuous response of Nemluvio up to 56 weeks in atopic dermatitis patients from the ARCADIA 1&2 trials and long-term extensi

• New pivotal study data demonstrating the safety and effectiveness of Sculptra, the only U.S. FDA-approved PLLA biostimulator, in the correction of cheek wrinkles to be presented.